Nucleic acid vaccines.
The use of nucleic acid-based vaccines is a novel approach to immunization that elicits immune responses similar to those induced by live, attenuated vaccines. Administration of nucleic acid vaccines results in the endogenous generation of viral proteins with native conformation, glycosylation profiles, and other posttranslational modifications that mimic antigen produced during natural viral infection. Nucleic acid vaccines have been shown to elicit both antibody and cytotoxic T-lymphocyte responses to diverse protein antigens. Advantages of nucleic acid-based vaccines include the simplicity of the vector, the ease of delivery, the duration of expression, and, to date, the lack of evidence of integration. Further studies are needed to assess the feasibility, safety, and efficacy of this new and promising technology.
Vogel
F R
FR
Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892, USA.
Sarver
N
N
D000818:Animals; D003257:Consumer Product Safety; D004247:DNA / Q000276:immunology*; D005544:Forecasting; D015967:Gene Expression Regulation, Viral; D018014:Gene Transfer Techniques; D006801:Humans; D051379:Mice; D010957:Plasmids; D051381:Rats; D012190:Retroviridae / Q000235:genetics / Q000276:immunology*; D012192:Retroviridae Infections / Q000517:prevention & control*; D014765:Viral Vaccines / Q000235:genetics*
D014765:Viral Vaccines; D004247:DNA